FRT vs PTGX · rev $1.28B vs rev $269.8M
FRT (FRT) versus Protagonist Therapeutics Inc (PTGX) — a side-by-side from cached financials, not a winner call.
FRT (FRT) common stock.
Protagonist Therapeutics Inc (PTGX) is a biotechnology company listed on NASDAQ.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
Latest reported PTGX revenue for 2026-06-30 was $269.8M. Net income was $166.6M. PTGX currently screens at market cap $7.25B.
FRT currently screens at market cap $0. PTGX currently screens at market cap $7.25B.
Not investment advice. Open the FRT and PTGX stock pages for the full models.
Not investment advice.